The vaccines are being developed with the mRNA technology that was used to make Pfizer’s coronavirus vaccine
London Thanasis Gavos
Thousands cancer patients in England they will have the opportunity to be included in a program – “milestone”, receiving a new one vaccine which will have been prepared exclusively for their own volume and organism.
“The NHS is uniquely placed to deliver this kind of world-leading research at such a wide scale and scale,” NHS England chief Amanda Pritchard said.
His program NHS entitled “Starting Point Cancer Vaccine” has already enrolled the first dozen patients and is expected to be offered to thousands, in 30 different hospitals across England.
The first trials will target specific types of cancer: colorectal, skin, lung, bladder, pancreas and kidney. More disease types may be added to the program in time.
The first patient who has already been given the personalized vaccine is 55-year-old Elliot Febve, a father-of-four and lecturer at Coventry University who is suffering from bowel cancer.
He received the vaccine after the tumor was removed and said he hopes his participation in the program will help thousands if not millions of patients find new hope.
How patients will be selected – What the vaccine ‘does’
In this “fast-track” process of inclusion in the clinical program for the administration of vaccines, those patients who meet certain medical criteria will be included after consenting to a blood test and an analysis of samples from the cancerous tumor they have manifested.
The vaccine teaches each patient’s immune system to recognize cancer cells that remain in the body after tumor removal surgery, to attack and kill them, even whenever they recur, promising a “permanent” cancer cure.
It is noted that research on this specific type of treatment is still considered to be at an early stage. However, trials so far have shown that vaccines of this type are indeed effective in killing any cancer cells that remain in the body after surgery to remove the tumor, as well as dramatically reducing the chances of recurrence.
The vaccines are being developed with the mRNA technology that was used to make Pfizer’s coronavirus vaccine.
The same German biotech company, BioNTech, is behind both vaccines and will present new research findings today at an oncology conference in Chicago.
Source :Skai
I have worked in the news industry for over 10 years. I have a vast amount of experience in covering health news. I am also an author at News Bulletin 247. I am highly experienced and knowledgeable in this field. I am a hard worker and always deliver quality work. I am a reliable source of information and always provide accurate information.
